Adenovirus expressing nc886, an anti-interferon and anti-apoptotic non-coding RNA, is an improved gene delivery vector
Enkhjin Saruuldalai,Hwi-Ho Lee,Yeon-Su Lee,Eun Kyung Hong,Soyoun Ro,Yeochan Kim,TaeJin Ahn,Jong-Lyul Park,Seon-Young Kim,Seung-Phil Shin,Wonkyun Ronny Im,Eunjung Cho,Beom K Choi,Jiyoung Joan Jang,Byung-Han Choi,Yuh-Seog Jung,In-Hoo Kim,Sang-Jin Lee,Yong Sun Lee
DOI: https://doi.org/10.1016/j.omtn.2024.102270
2024-07-16
Abstract:Recombinant adenovirus (rAdV) vector is the most promising vehicle to deliver an exogenous gene into target cells and is preferred for gene therapy. Exogenous gene expression from rAdV is often too inefficient to induce phenotypic changes and the amount of administered rAdV must be very high to achieve a therapeutic dose. However, it is often hampered because a high dose of rAdV is likely to induce cytotoxicity by activating immune responses. nc886, a 102-nucleotide non-coding RNA that is transcribed by RNA polymerase III, acts as an immune suppressor and a facilitator of AdV entry into the nucleus. Therefore, in this study, we have constructed an rAdV expressing nc886 (AdV:nc886) to explore whether AdV:nc886 overcomes the aforementioned drawbacks of conventional rAdV vectors. When infected into mouse cell lines and mice, AdV:nc886 expresses a sufficient amount of nc886, which suppresses the induction of interferon-stimulated genes and apoptotic pathways triggered by AdV infection. As a result, AdV:nc886 is less cytotoxic and produces more rAdV-delivered gene products, compared with the parental rAdV vector lacking nc886. In conclusion, this study demonstrates that the nc886-expressing rAdV could become a superior gene delivery vehicle with greater safety and higher efficiency for in vivo gene therapy.